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MicroRNAs (miRNAs) are endogenous short non-coding RNAs that repress post-transcriptional regulation of gene
expression, while embryonal central nervous system tumors are the foremost cause of mortality in children suffering
from a neoplasm. MiRNAs and their regulatory mechanisms are new to understand, while pediatric CNS tumors are
difficult to comprehend. Therefore, identification of the link between them composes a major scientific challenge.
The present study, reviewed the current knowledge on the role of miRNA in pediatric CNS embryonal tumors,
attempting to collect the existing information in one piece of work that could ideally be used as a guide for future
reference and research.
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Introducing microRNAs
MicroRNAs (miRNAs) are endogenous short non-coding
RNAs of 19–24 nucleotides in length that repress post-
transcriptional regulation of gene expression. Single-
stranded miRNAs are predicted to regulate 30% of all
genes and to target sequences in the 3’ untranslated region
(3’ UTR) of genes. They bind through partial sequence
homology to the 3’ UTR of target mature protein coding
messenger RNAs (mRNAs) and either inhibit mRNA
translation through RNA interference (RNAi) or less
frequently induce mRNA degradation. As a result, they
impact vital cellular and physiological processes including
differentiation, proliferation, growth, stress response, apop-
tosis and survival [1-3]. It has become increasingly evident
that deregulation of microRNAs is implicated in a wide
range of serious human diseases such as cardiovascular dis-
ease [4-8], neurological disorders [9], immune-mediated
disorders [10,11], viral infections [12], diabetes [13,14],
obesity [5,15-17], rheumatoid arthritis [13,18,19] and sev-
eral types of cancer [3,6,14,19-22] including breast cancer
[23-26], bladder cancer [27-29], and kidney cancer [30-33].* Correspondence: mbraoudak@med.uoa.gr
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article, unless otherwise stated.In general, we do not know much on the functionality and
role of miRNAs in pediatric tumors. As a remark, know-
ledge adds up with time while interpretation of complex
information lacks in progress. Yet, this is what makes bio-
logical phenomena so challenging and beautiful.Oncogenesis in childhood neoplasms
Clonal evolution and cancer stem cells
Substantial growing experimental evidence in several
malignancies has demonstrated that only a distinct subpop-
ulation of tumor cells, termed cancer stem cells (CSCs),
contain the ability to undergo self-renewal and differenti-
ation (properties of normal stem cells). Hence, they have
the ability to initiate tumorigenesis and support ongoing
tumor growth. Furthermore, it appears that, like their nor-
mal stem cell counterparts, CSCs have increased resistance
to standard cytotoxic therapies. These findings have
coalesced into the cancer stem cell hypothesis of
tumorigenesis, which has remarkable implications on
our understanding of tumor initiation, disease progres-
sion, and treatment response. In general, two major
models have been described for tumor propagation:
the clonal evolution model and the CSC hypothesis.
According to the clonal evolution model, neoplasms
arise from a single cell of origin and tumor progression
results from acquired genetic variability within the original
clone allowing sequential selection of more aggressive
sublines. The CSC hypothesis sustains that tumor cells areed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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proliferate extensively and form new tumors [34-37].
In general, CSCs are highly important to understand
the underlying tumor biology or pathogenesis. However,
even though there has been suggested that tumor growth
is sustained by a subpopulation of cells with stem-like fea-
tures, little is known on their genomic characterization
and their genetic stability.Neural stem cells
The cellular origin of pediatric brain tumors remains un-
clear. One possibility is that they arise by transformation
of proliferating neural stem cells (NSCs), which retain
the ability to self-renew and differentiate into neurons
and glia. There are several lines of indirect evidence in
support of this hypothesis including: a) Pediatric brain
tumors often contain multiple cell types suggestive of an
origin from a cell with multilineage potential; b) Several
pediatric brain tumors appear to arise from the ventricular
zone, which is the location of the NSCs; c) Both pediatric
brain tumors and NSCs express nestin, an intermediate
filament characteristic of several progenitors; d) Pediatric
brain tumors frequently express genes that regulate prolif-
eration and self-renewal of normal NSCs whilst mutations
in genes that normally regulate neural stem cell prolif-
eration are frequently found in pediatric brain tumors;
e) Forced expression of oncogenes in neural stem and
progenitors cells in Severe Combined Immunodeffi-
cient (SCID) mice produces tumors that are similar to
primary human tumors. In models of acute myeloid
leukemia for instance, CSCs have been isolated and re-
passaged into experimental animals to form novel tu-
mors, providing strong evidence that these cells are the
root cause of the tumor [38-43].Controversies
With respect to stem cells, a lot of debate has been done
on their role and their functionality in tumorigenesis.
Other theories have proposed that cancer could be a
“wound that never heals”, which along with the role of
the microenvironemt constitute the explosive mixture of
the disease. A very interesting issue addressed before
concerns the aspect of proliferation, which consists of a
tumor trait and regeneration which consists of a stem
cell trait [44]. Regeneration is closely linked to prolifera-
tion, while the opposite is not always true especially for
tumors. Yet, if we examine this aspect from the tumor
point of view then its proliferation that coincides with
its regeneration. This is a very delicate phenomenon and
the perspective of examination might lead to its compre-
hension. For example, there is a vast difference between
theorizing tumors as an abnormal condition and as a
normal evolutionary reaction.MicroRNAs and Childhood CNS Neoplasms
A search in the Pubmed Database returns a total of ~80
articles with the keywords “miRNA medulloblastoma”
and nine articles for “miRNA childhood Central Nervous
System Tumors”. This highlights the novelty of the sub-
ject of miRNA role in childhood neoplasms. Childhood
neoplasms of the central nervous system (CNS) are rare
with an incidence of less than five newly diagnosed cases
for every 100,000 births [45]. The discovery of miRNAs
has provided a wealth of knowledge regarding clinical
approach, diagnosis and treatment. Their potential as
specific disease biomarkers and targets of therapeutic
intervention holds great promise. Yet, we should keep in
mind our former remark that with increasing discovery
of elements of the tumor puzzle their comprehension
still falls behind.
Scope
In the present work, we will focus specifically on pediatric
central nervous system (CNS) embryonal tumors and the
role of miRNAs expression profiles. Herein, the emerging
role of miRNAs’ differential expression in the pathogen-
esis of pediatric central nervous system embryonal tumors
and their potential as therapeutic targets is addressed.
Pediatric CNS embryonal tumors
Pediatric tumors of embryonal origin are a heterogeneous
group of malignant neoplasms that comprise by far the
largest group of malignant brain tumors in childhood,
highly associated with increased mortality and long-term
morbidity. On the basis of their morphological, immuno-
histochemical and molecular features, these tumors are
broadly classified by the World Health Organization (WHO).
The newWHO classification on brain tumors has established
some relevant changes in the group of CNS embryonal
neoplasms. The above group of neoplasms is comprised
from several brain tumor types including medulloblas-
toma, CNS primitive neuroectodermal tumors, medulloe-
pithelioma, ependymoblastoma and atypical teratoid
rhabdoid tumor/rhabdoid tumor predisposition syndrome
[46]. The implicated miRNAs referred in the present work
are summarized in Table 1.
Medulloblastomas
Medulloblastomas (MB) are the most common malignant
pediatric neoplasms of the CNS and represent >20% of all
pediatric brain tumors. According to WHO classification,
MB grade IV is a malignant embryonal tumor of the cere-
bellum with a preferential manifestation in children, pre-
dominantly neuronal differentiation and an inherent trend
to metastasize via cerebrospinal fluid (CSF) pathways
[46]. Staging systems for MBs based on clinical parame-
ters including patient age, metastatic stage and patho-
logical variants are still widely employed in clinical






role with respect to
target-molecule/gene
miRNA regulating role to MB CNS
neoplasm
Reference
miR-124 ↓ compared to
normal brain tissue
CDK6 ↑ compared to
normal brain tissue
Interacts Suppresses proliferation, not
apoptosis
MB Pierson J, Hostager B et al. [58]
miR-124 ↓ compared to
normal brain tissue
SLC16A1 ↑ compared to
normal brain tissue
Suppression Suppresses proliferation, not
apoptosis
MB Li KKW, Pang JCS et al. [59]
miR-129 ↓ compared to
normal brain tissue
CDK6 ↑ compared to
normal brain tissue
Suppression Suppresses proliferation, not
apoptosis
MB Wu J, Qian J et al. [61]
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let-7 g ↓ in Classic,
Anaplastic,
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miR-30b ↑ in MB at 8q24.22-
q24.23
KHDRBS3 ↑ compared to
normal brain tissue
Correlates MB Lu Y, Ryan SL et al. [80]
miR-30d
miR-17 Mixed pattern of
expression
Distinguishes between MB
tumor tissue and adjacent
Normal tissue














miR-34a ↓ compared to
normal brain tissue




MB Guessous F, Zhang Y et al. [82]





MACE-A ↑ compared to
normal brain tissue
Suppression Enhances Chemosensitivity MB Weeraratne SD, Amani V et al. [84]
TP53 ↓ in MB Indirect promotion MB
miR-128a ↓ compared to
normal brain tissue
BMI1 ↑ compared to
normal brain tissue
Suppression Suppresses tumor growth
through senescence
MB Venkataraman S, Birks D et al.
[77]/Venkataraman S, Alimova I
et al. [78]
miR-142-5p ↓ compared to
normal brain tissue

















Table 1 Summary of miRNAs participating in CNS Embryonal Tumors (Continued)
miR-193a ↑ compared to
normal tissue

































miR-21 ↑ compared to
normal tissue
















Table 1 Summary of miRNAs participating in CNS Embryonal Tumors (Continued)
miR-128 ↑ compared to
normal tissue
Musashi1 ↑ compared to
normal brain tissue














MB Weeraratne SD, Amani V et al. [84]
miR-33b ↓ compared to
normal brain tissue
CMYC Its absence promotes MB, when
expressed represses MB
MB Takwi AA, Li Yet al. [79]
miR-383 ↓ compared to
normal brain tissue
PRDX3 Its absence promotes MB, when
expressed represses MB
MB Li KK, Pang JC et al. [88]
miR-494 ↑ compared to
normal tissue
SDC1 promotes angiogenesis MB Asuthkar S, Velpula KK et al. [89]
miR-218 ↓ compared to
normal brain tissue
SH3GL1 Suppression Cell survival, proliferation,
migration
MB Shi J, Yang L et al. [90]
miR-193a-3p ↑ compared to
normal tissue
WNT signaling pathway
(CTNNB1, WIF1, DKK2, MYC)
Promotion Cell survival, proliferation,
migration





miR-let-7f-1 ↓ compared to
normal brain tissue
regulator of cis-platin resisance MB Pannuru P, Dontula R et al. [92]
miR-31 ↑ compared to
normal tissue
MCM2 ↑ compared to
normal brain tissue
Suppression Inhibition of Chromatin
remodelling
MB Jin Y, Xiong A et al. [91]
miR-517c ↑ compared to
normal tissue
WNT signaling pathway
(API5, BAD, TRADD, SOX11,
NR2F1 NKX2-2, FGF13, FGFr3,
SALL4)
Promotion Cell survival, proliferation,
migration
PNET Li M, Lee KF et al. [102]
miR-520 g ↑ compared to
normal tissue
NKX2-2,OLIG1 Promotion
miR-let-7f-1 ↓ compared to
normal brain tissue
LIN28, IGF/PI3K/mTOR Promotion Cell survival, proliferation,
migration
PNET Spence T, Perotti C et al. [105]
miR-221 ↑ compared to
normal tissue
p27Kip1 ↓ in ATRT Suppression Tumor progression ATRT Sredni ST, de Fátima Bonaldo M
et al. [111]
miR-222 ↑ compared to
normal tissue

















Table 1 Summary of miRNAs participating in CNS Embryonal Tumors (Continued)
miR-517c ↑ compared to
normal tissue
ME/ EB Nobusawa S, Yokoo H et al. [109]
miR-520 g ↑ compared to
normal tissue
miR-371 ↑ compared to
normal tissue
miR-372 ↑ compared to
normal tissue
miR-373 ↑ compared to
normal tissue
miR-142-5p ↑ compared to
normal tissue






miR-140 ↓ compared to
normal brain tissue





miR-let-7a3 ↓ compared to
normal brain tissue
HMGA2 ↑ compared to
normal brain tissue
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true clinically and biologically heterogeneous nature of
these neoplasms [47-51]. The group of MB consists of:
a) classical b) desmoplastic/nodular c) MB with exten-
sive nodularity d) anaplastic large cell MB. Following
the WHO Classification, two new variants are recognized;
medulloblastoma with extensive nodularity and anaplastic
MB. Therefore, the descriptive terms MB with rhabdo-
myoblastic differentiation and MB with melanotic differ-
entiation have been proposed.
Although aggressive multimodal therapy has improved
the prognosis for children with MB, nearly half of all pa-
tients will eventually die from progressive tumors. More-
over, survivors often suffer significant treatment-related
morbidities, including neurocognitive deficits related to
radiation therapy. New insights into the pathogenesis of
these tumors are therefore sorely needed. Gene-based
research has identified two subgroups of MBs, one asso-
ciated with mutated genes within the Hedgehog pathway
and the other associated with altered Wingless-type
MMTV integration site family (WNT) pathway genes
[52]. It is noteworthy that children with WNT MBs have
improved survival [53]. Also, WNT MBs have manifested
significant over-expression of miR-193a-3p, miR224, miR-
148a, miR-23b and miR-365 [54]. Amplifications of MYC
and the transcription factor OTX2 [55], mutations in
TP53 [56], and a number of chromosomal alterations
have also been identified in MBs. These discoveries have
assisted to define the pathogenesis of MBs and have im-
proved the ability to identify patients who might benefit
from therapies targeting these pathways. However, most
MB patients do not have alterations in these genes and
the compendium of genetic alterations causing MB re-
mains to be determined.
MicroRNAs and Medulloblastomas
The first report on miRNA role in medulloblastoma was
published by Pierson et al. [58], in which it was found
that CDK6 was regulated by miR-124, a tumor suppressor
[57], and miR-24a was found to be a negative regulator
of SLC16A1 [58,59]. Later on, a similar report con-
firmed the interaction of another miRNA; miR-22, with
another member of this family of proteins, the PAPST1
(SLC35B2), indicating a constant down-regulation in
MBs and a potential inhibitory role in disease progres-
sion [60]. In addition, CDK6 was shown to be regulated
by miR-129, which functioned as a potential tumor sup-
pressor [61]. Further on, it has been reported that miR-
NAs interact with the Hedgehog pathway. In particular,
in a previous study it was found that MB tumors mani-
fest two categories of neoplasms based on the levels of
the GLI1 gene and respective protein that is those with
high levels and those with low levels. Smoothened (Smo)
is an effector of Gli1, which is activated and starts itstranscriptional activity. Both proteins are mediators of the
Hedgehog pathway, whose hyperactivity has been reported
in MBs, and thus its regulation could be of significance. In
that sense, it was found that miR-326, miR-135a, miR-
135b, miR-125b, miR-103, miR-203, miR-338, miR-324-
5p, miR-100, miR-153, miR-324-5p and miR-331 were
regulating Smo and Gli1, respectively [62]. The interesting
finding was that those miRNAs were downregulated in al-
most all MBs and their activation led to MB cell prolifera-
tion inhibition and growth [62]. Similarly, a second report
showed the significance of another miRNA in MB; miR-
17 ~ 92 cluster. It appeared that this miRNA was overex-
pressed in MBs and interfered with the Hedgehog pathway
[52,63,64], while its silencing inhibited MB progression
[65,66]. At the same time, it was found that miR-182 par-
ticipated in non-Sonic Hedgehog MBs, promoting migra-
tion [67]. Several miRNAs have been reported to be
associated with the Sonic Hedgehog and WNT pathways.
Those are summarized in Table 2, where MB tumors have
been separated into four groups, according to the report,
with the respective up- or down-regulated miRNAs and
some of the respective genes (second row) [68].
Another molecule of interest in MBs appeared to be
HES1. Persistent expression of bHelix-Loop-Helix (bHLH)
HES1, the principal Notch-responsive gene, prevented both
migration of neural progenitor cells out of the ventricular
zone and expression of neuronal markers [69] as well as
epigenetic silencing of miR-9 was also associated with
HES1 oncogenic activity [70]. In the same report, it was
shown that miR-199b-5p impairs MB progression, when
overexpressed, and reduced proliferation [69]. HES1 has
been found to be also regulated by miR-199b-5p along
with CD15 [71]. In a recent review, it has been reported
that miRNAs have been found to participate in a variety
of brain tumors. In particular, in Glioblastoma Multiforme
(GBM), several miRNAs such as miR-10b, miR-21, miR-
124 and miR-128-1 were reported to be deregulated, as
well as glioma stem cells were found to upregulated miR-
16, miR-107, miR-185, miR-425 and miR-486 [59,72]. Fur-
ther on, miR-21 when suppressed inhibited the potential
MB migration [73] and miR-128 regulated the RNA-
binding protein Musashi1 (expression of this gene has
been correlated with the grade of the malignancy and pro-
liferative activity in gliomas and melanomas) along with
miR-34a, miR-101, miR-128, miR-137 and miR-138 [74].
It has also been shown that miR-191, mIR-106b and
miR19a could distinguish between classic, anaplastic and
desmoplastic MBs. For miR-106b, it has also been re-
ported in a subsequent study that it was up-regulated in
MBs and interacted directly with PTEN, a critical signal-
ing molecule in disease progression [75]. Also, miR-10b,
miR-125b, miR-135a, miR-135b, miR-153 and miR-199b
were clustered and thus able to differentiate between
ERBB2 high and low expression in MBs, while miR-128-1,
Table 2 miRNAs implicated in MB and the WNT, SHH signaling pathways Gokhale et al. [68]
A B C D
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tween CMYC high and low expression MBs [76]. MiR-
128a was also reported to inhibit MB growth, yet
through senescence, by targeting BMI1, a gene which
is a component of a Polycomb group (PcG) multipro-
tein PRC1-like complex, which is required to maintain
the transcriptionally repressive state of many genes, in-
cluding Hox genes, throughout development. It is dir-
ectly involved in embryonal tumors and erythroplakia
[77,78]. The cMYC was also found to correlate with
miR-33b, which when expressed represses MB promo-
tion. The 17p11.2 locus is usually missed in MBs and it
is the location of miR-33b [79].
Another miRNA studied was miR-30b and miR-30d,
which appeared to be upregulated in MBs with the amp-
lification 8q24.22-q24.23, along with KHDRBS3 gene; an
RNA-binding protein that plays a role in the regulation
of alternative splicing and influences mRNA splice site
selection and exon inclusion [80]. One of the few micro-
arrays miRNA analyses performed in 2009 by Liu et al.
showed the potential differences between MB tissue andadjacent normal tissue. The miRNAs reported are of
interest since it is known that tumors interact with their
microenvironment, thus those miRNA could be poten-
tial targets of MB functionality and metastasis [81].
Returning to the individual miRNA roles, an additional
report showed that miR-34a was a potential tumor sup-
pressive gene and interacted with CMET and NOTCH1.
Both, are considered known genes for their role in
tumorigenesis and tumor ontogeny [82,83]. Additionally,
the same miRNA has been found to be involved in che-
mosensitivity through regulation of MAGE-A and p53 in
MBs [84], as well as regulating the RNA-binding protein
Musashi1 [74]. When comparing several CNS tumor
types, a report found two miRNAs that were upregulated
in all types. Those included miR-142-5p and miR-25,
which appeared to be upregulated in GBM, MB AT/RT,
EPN and PA. Probably, those miRNAs could be regarded
as common regulators for CNS tumors [85]. In some
most aggressive types of MD, associated with MYC amp-
lification, the group of miR-183 ~ 96 ~ 182 cluster has
been found to be implicated in MB survival, proliferation
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axis [86,87]. Another recently reported miRNA, miR-383
was down-regulated in MBs, while when ectopically
expressed inhibited growth and MB survival through
PRDX3 regulation [88].
The role of miRNAs is being more and more elucidated
as novel mechanisms are being revealed. In a very recent
report, it was proposed that ionizing radiation (IR)-in-
duced MMP-9 enhances SDC1 shedding, corroborating to
tube-inducing ability of MB cells. Furthermore, it has been
reported that tumor angiogenesis is associated with higher
MMP-9-SDC1 interactions on both the cell surface and
extracellular medium, revealing that the existence of a
novel regulatory mechanism where MMP-9 drives the
suppression of miR-494, resulting in enhanced SDC1
shedding and angiogenesis. Hence, it has been found that
MMP-9-specific shRNA treatment of mouse intracranial
tumors resulted in elevated expression of miR-494. Fur-
ther analysis showed that SDC1 mRNA is a direct target
of miR-494 [89]. Another miRNA identified was miR-218,
a tumor suppressor, which is down-regulated in MB dir-
ectly targeting SH3GL1, a gene whose overexpression may
play a role in leukemogenesis, and the encoded protein
has been implicated in acute myeloid leukemia as a fusion
partner of the myeloid-lymphoid leukemia protein [90].
Two novel reports have shown that miR-31 suppresses
MB by inhibiting MCM2 [91] and lastly, that miR-let-7f-1
is a regulator of cis-platin resistance in MB cells [92].
Up to this point, it is apparent that the knowledge
gathered has been essential for understanding the role
of miRNAs in MB. Yet, it is also quite obvious that fur-
ther research is necessitated in order to comprehend
the complicated mechanisms of MB progression and
oncogenesis.
Primitive Neuroectodermal Tumors (PNETs)
Central nervous system primitive neuroectodermal tumors
(PNETs) are a heterogeneous group of tumors occurring
predominantly in children and adolescents, arising in the
cerebral hemispheres, the brain stem and spinal cord.
CNS PNETs are composed of undifferentiated or poorly
differentiated cells, which may display divergent differenti-
ation along neuronal, glial or ependymal cell lines. Fea-
tures common to all CNS PNETs include early onset and
aggressive biological behavior. The term CNS PNET en-
compasses: a) CNS supratentorial PNET, (CNS PNET)
embryonal tumors composed of undifferentiated or poorly
differentiated neuroepithelial cells that occur at any extra-
cerebellar site b) CNS neuroblastomas, tumors with only
neuronal differentiation c) CNS ganglioneuroblastomas
when ganglion cells are also present d) medulloepithe-
liomas, tumors with features of embryonal neural tube
and e) ependymoblastomas. Moreover, an unusual PNET,
called embryonal tumor with abundant neutrophil andtrue rosettes occurring in the cerebrum of young children,
is mentioned as a provisional entity.
The cytogenetics of PNETs are considered better
understood than the rest pediatric CNS tumors, with
several recognized, nonrandom chromosome abnormal-
ities. The most frequent observed in 30–40% of cases, is
loss of 17p, usually through the formation of an isochro-
mosome of 17q [93,94]. Additional regions of genetic
imbalance also have been demonstrated using microsat-
ellite analysis [95] and CGH [96,97] with some studies
suggesting genetic differences between intratentorial and
supratentorial PNET [98,99]. In general, investigations
on supratentorial PNETs are infrequent, however despite
the small number of genetic studies, CNS/suprantetorial
PNET show different genetic alterations than medullo-
blastoma, which argues against the previously proposed
theory; PNET concept, for common histogenesis. CNS
supratentorial PNETs usually show no loss of 17p, i17q
and patched (PTCH) gene mutations, which characterize
medulloblastomas. In contrast, supratentorial PNETs ex-
press neurogenic transcription factors of the NeuroD
family and HASHI, a neurogenic transcription factor not
detected in MB. It is notable that children with supra-
tentorial PNETs, especially those less than 2 years old,
have a dismal overall 5 year survival than children with
medulloblastoma, suggesting that there might be add-
itional, yet unknown constitutional genetic aberrations
underlying the pathogenesis of PNETs.
MicroRNAs and PNETs
There are not many reports concerning this type of em-
bryonal tumor with miRNAs. One report has found that
in an embryonal tumor cell line miR-let-7 is linked to
mTOR signaling and the miRNA remains underex-
pressed and it is upregulated in LIN28 knockdown cells
along with IGF/PI3K/mTOR pathway signaling silencing
[100]. This finding was important since LIN28A is con-
sidered to be a diagnostic marker for embryonal tumors
and thus its expression could be of critical significance
for disease progression [101]. One report that dealt with
PNETs has mentioned that miR-517c and miR-520 g
promoted oncegenicity interacting with WNT signaling
[102]. As in the case of MBs also in PNETs similar signal-
ing pathways are implicated hinting towards a common
machinery in CNS Embryonal tumors, which remains to
be elucidated. The functions of miRNA in neuroectoder-
mal tumors are not limited to the CNS but numerous re-
ports have reported a role in neuroblastoma or even
Ewing Sarcoma /PNET [103,104].
Other embryonal tumors
Medulloepitheliomas (ME)
According to WHO 2007, medulloepithelioma (ME) grade
IV is a rare malignant embryonal neoplasm affecting
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becular arrangement of neoplastic cells recapitulating the
features of embryonal neural tube. MEs are affecting chil-
dren between 6 months and 5 years with 50% occurring
during the first 2 years of life. Congenital cases and cases
occurring beyond the first decade have been reported. The
periventricular area is the most common site in the cere-
bral hemispheres involving mainly the temporal and par-
ietal lobes. ME may arise intraventricularly, in the sellar
region, cauda equine and presacral area. Intraorbital ME
rarely metastasize and have a favorable prognosis, while
optic nerve tumors carry an intermediate prognosis be-
tween intraorbital and cerebral tumors. The differential
diagnosis of ME includes: a) ependymoblastoma, char-
acterized by predominant ependymoblastic rosettes, b)
choroid plexus carcinomas, which are strongly Cytoker-
atin + without the characteristic neuroepithelium, c) im-
mature teratoma that contains tissues from the three
germ layers and d) AT/RT, which shows loss of nuclear
INI1 protein. ME is considered a very aggressive neo-
plasm, since most children are dying within a year of
diagnosis. Histologically MEs recreate the features of
embryonal neural tube. They are composed of a) tubu-
lar, papillary and trabecular arrangement of neuroepi-
thelium with a limiting external membrane and b)
sheets of undifferentiated cells and areas with divergent
differentiation. The diagnostic feature of ME is the
pseudostratified neuroepithelium arranged in papillary
and tubular structures composed of cuboidal and col-
umnar cells with the nuclei perpendicular to the inner/
outer surface showing nucleoli and luminal mitoses. Im-
munohistochemistry reveals in the neuroepithelial com-
ponent expression of nestin and vimentin mainly
confined to the basal area of the stratified epithelium. In
neuronal areas, variable expression of Synaptophysin,
Neurofilaments, EMA and cytokeratins has been ob-
served, while there is no detection of glial fibrillary acid
protein (GFAP), S-100 and neuron specific enolase
(NSE). In the areas distinct from the neuroepithelium,
variable expression of synaptophysin, neurofilaments
and MAP2 is seen in neuronal areas, while GFAP ex-
pression is variable/limited in undifferentiated areas,
while increasing in areas of astrocytic differentiation.
The histological/immunohistochemical resemblance of
ME with embryonal neural tube favors its derivation
from a progenitor in the subependymal area. The overall
picture regarding the genetic profile is somewhat vague
and therefore needs to be verified.
MicroRNAs and MEs
As in the case of PNET, a basic player in ME is LIN28,
which co-existing with a C19MC amplification consists
of a distinct histogenetic, diagnostic and therapeutic en-
tity as recently reported [105]. The presence of C19MCamplification has been also highlighted for embryonal tu-
mors as it has been shown that embryonal tumor onco-
genesis is driven genetically by the fusion of TTYH1 to
C19MC involved in fetal neural development [106].
Ependymoblastomas (EB)
According to WHO 2007, ependymoblastoma Grade IV
is a rare embryonal neoplasm affecting mainly infants
and young children. Ependymoblastomas are aggressive
tumors with craniospinal dissemination and fatal outcome
in 6 months to 1 year. Histologically, they are primitive
neuroectodermal tumors with increased cellularity and
characteristic ependymoblastic rosettes. The rosettes
are multilayered and form concentric rings around a
well-defined central lumen. Their nuclei are pushed
away from the lumen and the apical surface of the cells
show blepharoplasts and forms a distinct internal mem-
brane. The outer layer of the cells merges with the adjacent
undifferentiated neuroepithelial cells. Immunohistochemis-
try in a limited number of cases reveals expression of
S-100, vimentin, cytokeratin, GFAP, carbonic anhy-
drase isoenzyme II, rarely neurofilaments 68.160.200
Kda. The tumors are presumed to derive from periven-
tricular primitive cells. The term ependymoblast implies
an incompletely differentiated cell with glial-ependymal
features and immature characteristics. They are associated
with inferior prognosis but sustained remissions have been
achieved after multimodal treatment [107]. Moreover, they
are considered diagnostically challenging subtypes of em-
bryonal tumors, whose genetic features remain unknown.
Previous work suggested that ependymoblastomas show
distinct and fairly consistent chromosomal aberrations
[108]. However, the relative contributions of the different
genetic changes to disease pathogenesis need to be veri-
fied in larger studies.
MicroRNAs and EBs
This is also a tumor type that manifests the 19q13.42
amplification and is linked to the previously mentioned
miRNA cluster; C19MC, with specifically the miR-371-
373 being up-regulated [109]. In addition, the same study
manifested the up-regulation of miR-517c, miR-520 g,
miR-371, miR-372 and miR-373 in ependymoblastoma
and medulloepithillioma tumors.
Atypical teratoid rhabdoid tumor /rhabdoid tumor
predisposition syndrome (AT/RTs)
Atypical Teratoid Rhabdoid Tumor /Rhabdoid Tumor
predisposition syndrome (RTPS) is a disorder character-
ized by an increased risk to develop malignant rhabdoid
tumours (MRT) generally due to constitutional loss or in-
activation of one allele of deletion INI1/hSNF5/SMARCB1
gene located on chromosome 22q11.2. Children with mul-
tiple MRT or with affected siblings or with other relatives
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ial cases are rare. Atypical Teratoid Rhabdoid tumour
(AT/RT) is a highly malignant CNS tumour predominantly
in young children, with a male preponderance, typically
containing rhabdoid cells often with primitive neuroecto-
dermal cells and divergent differentiation along epithelial,
glial, neuronal, mesenchymal-like lines. AT/RT represents
1-2% of paediatric brain tumours and accounts for at least
10% of CNS tumours in infants, due to the predominance
in children younger of 3 years old. It can be supratentorial,
especially in cerebral hemispheres less frequently in the
ventricular system, supraselar region and pineal gland, or
intratentorial, especially in the cerebellar hemispheres, cer-
ellopontine angle, brain stem mainly in children younger
than 2 years of age.
Histologically, the hallmark of AT/RT is heterogeneity.
Rhabdoid cells are the characteristic features in many
cases, corresponding to cells with eccentric nuclei con-
taining fine chromatin and a prominent eosinophilic nu-
cleolus, well-defined abundant eosinophilic cytoplasm
with a globular inclusion. Rhabdoid cells are character-
ized by morphological variation, being large with less
atypic, abundant finely granular cytoplasm or cytoplas-
mic vacuolization. Nests, sheets or a jumbled appearance
of rhabdoid cells is observed, while they represent the
predominant cells only in the minority of AT/RT. Most
neoplasms have variable components with PNET-like,
mesenchymal and epithelial features.
Immunohistochemistry reveals expression of various
markers reflecting the polyphenotypic differentiation of
AT/RT. More specifically, it shows strong vimentin re-
activity as well as the epithelial membrane antigen,
smooth muscle actin, GFAP, cytokeratin, desmin, S-100
protein and neuron specific enolase. The above markers
are variably expressed in areas with different histological
patterns. Pathogenesis of AT/RT remains unknown.
Based on commonly found INI1 gene inactivation, it is
considered that lack of INI1 protein might play a signifi-
cant role in the process. In general, prognosis of AT/RT
is dismal while there are no protocols aimed specifically
for AT/RT. The vast majority of children receive platinum-
based and alkylator-based regimens which are commonly
recommended for brain tumours in infants. Therefore, it
is essential to identify novel therapeutic targets.
MicroRNAs and AT/RTs
In a recent report, it was found that two miRNAs; miR-
221 and miR-222 are participating in AT/RT ontogenesis.
In particular, it was found that those miRNAs are potent
regulators of p27Kip1, a tumor suppressor molecule, mem-
ber of the CDK family of inhibitors [110]. Those miRNAs
have been found to be up-regulated in AT/RTs thus
inhibiting the p27Kip1 function and allowing the tumor
to progress [111]. In another report, it was reportedthat miR-142-5p and miR-25 were up-regulated in AT/
RTs as compared to normal tissue, while miR-129 was
down-regulated in AT/RTs as compared to normal tis-
sue [85]. Collectively, in the same report the up-
regulated miRNAs in AT/RTs included, miR-520b,
miR-629, miR-221, miR-448 and miR-373, while the
down-regulated miRNAs were miR-140, miR-let-7b,
miR-139, miR-153 and miR-376b [85].
A different study that compared the expression levels
of miR-517c, miR-520 g, miR-371, miR-372 and miR-373
showed that there was no amplification of the genes as
compared to ependymoblastoma and medulloepithilioma
[109]. Another recent report studied the differences be-
tween AT/RT and Rhabdoid Tumors of the Kidney (RTK)
trying to identify miRNAs that would separate the two
tumor types. It was found that there were no miRNAs that
could distinguish between the two tumor types, probably
due to the fact that both are of the same origin, irrespec-
tively of the focal point [112]. MiR-let-7a3 and miR-let-7b
were found to be down-regulated in AT/RTs and at the
same time significantly reversibly correlated to HMGA2, a
gene that encodes a protein that belongs to the non-
histone chromosomal high mobility group (HMG) protein
family. HMG proteins function as architectural factors
and are essential components of the enhancesome. This
protein contains structural DNA-binding domains and
may act as a transcriptional regulating factor. Identifica-
tion of the deletion, amplification, and rearrangement of
this gene that are associated with myxoid liposarcoma
suggests a role in adipogenesis and mesenchymal differen-
tiation [25]. In a most recent report on AT/RTs, it was
mentioned that a subpopulation of CD133(+) cells isolated
from AT/RT tumors is present, having cancer stem-like
and radio-resistant properties. It was shown that expres-
sion of miR142-3p was lower in AT/RT-CD133(+) cells
than in AT/RT-CD133(−) cells. miR142-3p overexpression
significantly inhibited the self-renewal and tumorigenicity
of AT/RT-CD133(+) cells. On the contrary, it was found
that silencing of endogenous miR142-3p dramatically in-
creased the tumor-initiating and stem-like cell capacities
in AT/RT cells or AT/RT-CD133(−) cells and further pro-
moted the mesenchymal transitional and radio-resistant
properties of AT/RT cells [113]. As opposed to MB tu-
mors, AT/RTs are less studied and there is still a lot to be
learned about their underlying biology and pathogenesis
mechanisms.
Microrna detection-current methodologies
Discussing miRNAs is one thing, but detecting them is
another. Considering the fact that miRNA abundance is
at low percentages within the total RNA quantity, it is
necessary that detection methods should be accurate
and precise [114]. The good news is that such methods
exist and are extremely helpful in detecting miRNA
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could be separated into the following categories: Polymer-
ase Chain Reaction (PCR)-based methods, which include
both simple PCR as well as quantitative Real-Time PCR
(RT-qPCR), microarray based methodologies, Northern
blot analyses, in situ hybridization and last but not least
Next Generation Sequencing (NGS) methodologies [115].
Each of the aforementioned methods has its own benefits
and drawbacks. We could make a brief discrimination if
we would say that they can be divided into two major cat-
egories: those that can detect a small number of miRNAs
and those that can detect large numbers of miRNAs
simultaneously. To the first category belong the PCR
methodologies (even though the use of plates in the case
of RT-qPCR could classify them to the high-throughput
methods, it is still low in number as compared to the
other methods), blotting and in situ hybridization. To
the other end microarray-based platforms and NGS are
capable of detecting and examining the complete “miR-
Nome” in an experiment, a fact that makes them very at-
tractive for discovery-based investigations. On the other
hand, RT-qPCR affords the gold standard in miRNA de-
tection and quantification. This method is frequently re-
quired following a high-throughput experiment in order
to verify the obtained results. qRT-PCR is difficult to be
used in high-throughput analysis [116] and it is also
considered an expensive technique, however it is less
time consuming than microarrays and NGS and does
not require complex data processing by biostatisticians
[117]. At the same time, Northern blot analysis remains
an undisputable tool in gene expression validation, yet it
has a drawback involving the time consumed, the poor
sensitivity [118] and the amount of available miRNA in
a given sample [115]. The latter detail leads to poor sen-
sitivity in miRNA detection and can be surpassed only
by the excessive use of sample, which is not always pos-
sible. In situ hybridization methods although provide
sensitive miRNA detection, are considered semi-quantitative
in contrast to capillary electrophoresis techniques which
allow simple quantitative analysis with high resolving
power [118]. Last but not least, the NGS methods are be-
coming a powerful tool in the detection of miRNA expres-
sion since they cannot only detect the abundance of
miRNA in a sample but also the presence of novel, un-
known miRNAs as well as miRNA mutations. It is very
probable that this methodology will replace all previous,
with time, both in research as well as in the clinical praxis.
Its cost remains high but it is decreasing as novel plar-
forms are developing [117].
Therapeutic applications
MicroRNAs are considered attractive therapeutic tools
for at least two reasons; they are low toxicity for their
endogenous expression and due to their multi-targetingproperties. Regulation of miRNA expression can be
achieved in several ways. One approach to design syn-
thetic miR-like small RNA molecules, which would
suppress the production of proteins known to be in-
volved in certain disease conditions. An additional
strategy would be to target endogenous miRs either by
mimicking the effects of miRs that are pathologically
underexpressed in disease or by antagonizing the effects
of miRs that are abnormally overexpressed in disease.
Antagomirs are of major interest since they are deliv-
ered to almost all tissues, with the exception of the brain,
following injections systemically or locally. Of note, ac-
cording to Wang et al. [119], this miRNA feature might
bring about ‘off-target’ side-effects [119]. Nevertheless,
antagomirs against miR-21 have been successfully used to
inhibit fibrosis of heart and attenuate cardiac dysfunction
[120]. Furthermore, a miR-133a directed antagomir has
previously been employed to prevent hypertrophy [121].
Even though, antagomirs have proved extremely valuable
in the laboratory, yet there is a long way until miR-based
therapeutic strategies are implemented in human disease.
Most importantly, therapeutic delivery of miR142-3p in
AT/RT cells effectively reduced its lethality by blocking
tumor growth, repressing invasiveness, increasing radio-
sensitivity, and prolonging survival time in orthotropic-
transplanted immunocompromised mice.
Blocking oncogenic miRNAs can be achieved by the use
of antisense oligonucleotides, miRNA sponges, miR-masks
and small RNA inhibitors [122]. The most straightforward
method to inhibit miRNA repression of protein expression
uses anti-miRNA oligonucleotides (AMOs) to specifically
restrain interactions between the miRNA induced silen-
cing complex (RISC) proteins and the miRNA or miRISC
and its target mRNAs [87,123]. An additional approach is
to block the activity of a specific miRNA using a competi-
tive inhibitor known as a miRNA sponge or target mimic,
which contains binding sites for the miRNA either in a
non-coding transcript or in the 3’ untranslated region
(UTR) of a reporter gene [124]. Small-molecule miRNA
inhibitors can regulate miRNA expression at the tran-
scriptional level [122].
Enhancing of miRNA expression requires more factors
to be taken into account than blocking a specific miRNA.
Normally, increasing the expression of a molecule requires
the repression of a blocking precursor or the direct
addition of the desired molecule. Both of these tech-
niques are difficult to achieve at least in vivo. This type
of application is called miRNA replacement therapy
through the use of miRNA mimics. In order to achieve
similar biological function as the naturally produced
miRNAs, mimics should enter the RISC complex and
affect miRNA target mRNAs [87,123].
Several reports have shown that it is possible to introduce/
deliver therapeutic miRNAs through viral vector-based
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ally, several studies have reported the insertion of miRNAs
or the enhancement of their expression in vitro [129,130].
In general, materials for miRNA and anti-miRNA delivery
include lipid-based systems, polyethylenimine-based sys-
tems, dendrimers, poly(lactide-co-glycolide) particles and
other non viral delivery systems including naturally occur-
ring polymers such as chitosan or atelocollagen, among
others [87,123]. Additionally, hemispheres and hydrogels
have also been developed as gene delivery vehicles [122].
So far, significant advances have been made in the devel-
opment of miRNA-based therapies for cancer and other
human diseases. Mirna Therapeutics™ has initiated a Phase
1 clinical study with. MiRX34, which is a liposome-
formulated miRNA mimic of the tumor suppressor
miR-34, for use in patients with liver cancer or metastatic
cancer with liver involvement. This study is currently
recruiting participants to evaluate MRX34 safety [131].
Certainly, there are several limitations in the use of
miRNAs as therapeutic targets. Some of these limita-
tions apply not only to miRNAs but to other therapeutic
targets including proteins or genes and some others
apply miRNAs alone. A general rule of target investiga-
tion and usage is the lack of knowledge on basic mecha-
nisms. Since, biological systems tend to be extremely
complicated the time of unraveling their unknown role
is disproportionate to the need for therapies. Especially
for miRNAs, their biology is still largely unknown and
the question whether the aberrant expression of such a
molecule is due to the disease or it takes place during a
physiological process still remains unanswered. Yet, up
to date, this is a global issue in target discovery that has
not been dealt with. Of note though, miRNAs possess
several advantages as compared to other molecules.
They are small and their targets (as far as we know) are
genes [122]. Blocking or enhancing a miRNA could
probably produce avalanche effects and has an optimum
result with respect to therapy. However, effective delivery
and selective target delivery still remain an issue, since
their side- effects could be disproportionate to their size.
Especially, in the case of CNS tumors there is another
obstacle that should be overcome, that is the Blood–
brain-Barrier. This particularity of the brain requires the
use of sophisticated techniques in drug delivery but also
calls an extreme caution towards the adverse effects that
miRNAs could have in the brain [132]. In the discussion
about therapy, a very important factor should not be
omitted. This includes the use of miRNAs as prognostic
markers for chemotherapy and radiotherapy. Several re-
ports have highlighted this aspect as it has been shown
that the over- or down-regulation of specific miRNAs is
linked to sensitivity to classical anti-cancer therapies
[115,133-136]. This fact makes miRNAs even more
promising markers for cure since their dual role of eitherbeing the medication per se or the prognostic factor
gives them great value for further investigations.
Challenges in microrna biology and use
It is a general belief that the ultimate end-point in miRNA
discovery is their use for clinical purposes, either prognos-
tic or therapeutic. Yet, besides those noble tasks, miRNAs
could serve as amplifiers of knowledge in more basic sci-
entific questions such as evolution and biological mechan-
ics per se, that understand their role in the preservation of
life. It is not overstated if we say that the discovery of miR-
NAs has added another unknown variable in the equation
of biological systems. From that point of view, efforts
should continue towards the discovery of basic mecha-
nisms underlying miRNA functions and role.
On the other hand, clinical applications still have some
obstacles to overcome. The first comes from our previ-
ous point that referred to the lack of basic knowledge on
miRNA biology. The second comes from application is-
sues such as effectiveness of delivery, off-target effects,
side-effects and final accuracy of treatment. To our view,
an effective way of clinical use, towards therapy, would
the discovery of up-regulated miRNAs in tumors and its
subsequent blocking rather than the mimicking of a
miRNA. On the other hand, recent development in
miRNA discovery has given very promising results towards
their use as prognostic factors and the subsequent use
in improving classical therapies.
Concluding remarks
In summary, even if miRNAs appear as promising thera-
peutic targets, there is still a huge gap between mi-RNA
basic research and application to clinical settings. Drug
efficacy and toxicity studies are warranted to enhance
our knowledge about the impact of miRNA-directed
therapeutics before proceeding to clinical treatments.
Therefore, advancing our understanding regarding the
role of miRNAs expression profiles and their involve-
ment in translational regulation holds a promising fu-
ture for pharmacogenomics. Another comment that we
could make on the mechanistic nature of miRNAs is
that a basic observation we have done was that similar
miRNAs participate in similar signaling pathways and in
different neoplasmatic types. This is a hint towards a
probable common mechanistic regulatory mechanism
in CNS tumors, with great implications for disease prog-
nosis and therapy. Therefore, it is justified to say that miR-
NAs are currently the grand known unknown.
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